Volume : 12, Issue : 04, April – 2025
Title:
IN-SILICO AND IN-VITRO PHARMACOLOGICAL EVALUATION OF SULFAMETHOPYRAZINE AS ANTI-DIABETIC AGENT
Authors :
Saranya T.J, Soumya Surendran, Sneha Sanal, Abhijithmohan, Lekshmi Krishna V.B, Savitha Mol G.M
Abstract :
Background Of The Study: The present study aim to evaluate the Anti-diabetic property of Sulfamethopyrazine using in-silico, in-vitro, Swiss ADME and Antioxidant evaluation.
Methods: The data of Sulfamethopyrazine was collected from pubmed, pubchem, google scholar. By using software’s such as pyrex and pymol, Sulfamethopyrazine was docked with Antidiabetic receptors 3OLI and 4W93. The drug was brought from Chennai in the month of April. Then in-vitro studies were performed by using Glucose uptake assay and Inhibition of endogenous glucose production methods. Antioxidant evaluation was carried out by using DPPH method. Pharmacokinetic evaluation was done by using Swiss ADME Software.
Keywords: Anti-diabetic property, Sulfamethopyrazine, Docking , In-silico Method, In-vitro Method, Swiss ADME, Antioxidant evaluation, DPPH radical scavenging assay method.
Cite This Article:
Please cite this article in press Saranya T.J et al., In-Silico And In-Vitro Pharmacological Evaluation Of Sulfamethopyrazine As Anti-Diabetic Agent., Indo Am. J. P. Sci, 2025; 12(04).
Number of Downloads : 10
References:
1. Roshan kumar, Purabi Saha, Yogendra Kumar, SoumitraSahana, Anubhav Dubey and Om Prakash; World Journal of pharmacy and pharmaceutical science; vol.9;Page no; 2020;838850.
2. M.B. Adinortey; Advances in Biological Research 11(6); Vol.13; 2017; Page no: 382-390. 3. Habtamu Wondifraw Baynest; Journal of Diabetes and Metabolism; vol.6; 2015; Page no: 2- 6.
4. Michael Antolovich, Paul D. Prenzler, Emilios Patsalides, Suzanne McDonald andKevin Robards, The Royal Society of Chemisty; vol.127; 2001; pg.no :183-198. 5. K. D Tripathi, Essentials of Medicinal pharmacology; 7th edition; 2013; 704-705. 6. Yani Suryani, Opik Taupiqurrohman, Ai Rikani and EPA Paujiah; EDP Sciences; vol.21; 2018; page no: 1-5.
7. Sahil Singla, the Pharma Innovation Journa; SP-11(6), 1925-1927. Maria J. Meneses, Current Pharmaceutical DesignVol. 21; 2015; pg no. 25, 3608-3610.
8. Burton, D.G. A, and Stolzing, A. Cellular senescence: immunosurveillance and future immune therapy (2018); 43:17-25.
9. Cantuti-Castelvetri, L. Fitzner, D. Boch-Queralt, M. Wein, M.T. Su, M. Sen, Petan, Defective cholesterol clearance limits remyelination in the aged central nervous system Science.2018; 684-688.
10. Maitra A, Abbas AK, Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7th Edition) 2005. Philadelphia, Saunders; 1156-1226.
11. Galtier F. Definition, epidemiology, risk factors Diabetes; 2010; 36:628–651. 12. Arora, S., Ojha, S.K., Vohora, D., Characterisation of Streptozotocin induced diabetes mellitus in Swiss Albino mice, Glo J of Pharmacol; , 2015; 3(2): 81-84 .
13. Zhou F, Furuhashi K, Son MJ, Toyozaki M, Yoshizawa F, Miura Y, Yagasaki K.J.of health sci; Antidiabetic effect of enterolactone in cultured muscle cells and in type 2 diabetic model db/db mice. Cytotechnology; 2007 53(6); 660-662.
14. Steven D. Mittelman and Richard N. Bergman; Am J Physiol Endocrinol Metab; Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin; 1999; 630-636.
15. Chang ST, Wu JH, Wang SY, Kang PL, Yang NS, Shyur LF. ; J Agric Food Chem;Antioxidant activity of extractsfrom Acasia confuse bark and heartwood; 2001; 49:3420-3424.
16. Jean Gonfi M. Mvondo, Aristote Matondo, Dani T. Mawete, Sylvie Mireille N.Bambi, Blaise M. Mbala, Pierre O. Lohohola; International Journal of TROPICAL DISEASE & Health; in silico ADME/T Properties of Quinine Derivatives Using Swiss ADME and pk CSM Web servers; 2021;42(11); 2278-1005.
17. K. D Tripathi, Essentials of Medicinal pharmacology; 7th edition; 2013; 10-60. 18. Jothivel, N., Ponnusamy, S.P., Appachi, M., Antidiabetic activities of methanol leaf extract of Costus pictus D. Don in alloxan-induced diabetic rats, J of health sci.,53(6): 2007; 655663 . 19. Maria J. Meneses, Current Pharmaceutical Design; Vol. 21, No. 25;2015; 3608-3610 20. Miriam Cnop, Nils Welsh and Decio L. Eizirik, Diabetics, Vol .54, supplement II; 2005; S100- S101.
21. Sahil Singla, The Pharma Innovation Journal 2022; SP-11(6); 1925-1927 22. Maria J. Meneses, Current Pharmaceutical Design; Vol. 21; No. 25; 2015; 3608-3610 23. Sasikala P R, Meenal k. s ;Innovare Journal of Life science; in-silico molecular docking studies of multipotential compounds isolated from premna serratifolia L; 4(3); 2016; 1-8. 24. Burton, D.G. A, and Stolzing;A. Cellular senescence: immunosurveillance and future immune therapy; 43:2018; 17-25.
25. Cantuti-Castelvetri, L. Fitzner, D. Boch-Queralt, M. Wein, M.T. Su, M. Sen, Petan; 2018; Defective cholesterol clearance limits remyelination in the aged central nervous system. Science; 359; 684-688.
26. Aline Augusti Boligon1; Med chem, an open access journal, Volume 4(7):2014; 517-522– 517.
27. Gallagher AM Flatt PR, Duffy G, Abdel-Wahab YH A; The effects of Traditional Antidiabetic plants on in vitro Glucose Diffusion Nutrition Research; 2003; 23:43-424. 28. Manikandan R, Vijaya Aanad A and Durai Muthumani G;2013; International Journal of Current Microbiology and Applied Sciences; “Phytochemical and in vitro anti-diabetic activity of methanolic extract of Psidium guajava leaves”. 2(2); 15-17.